<?xml version="1.0" encoding="UTF-8"?>
<EmailTemplate xmlns="http://soap.sforce.com/2006/04/metadata">
    <available>true</available>
    <description>7/17/20 changed sender to Adriana. 2/20 Created by AF for Auto IOEs for On-Label matches</description>
    <encodingKey>ISO-8859-1</encodingKey>
    <name>1D2_Automated IOE On Label (Do Not Use for Manual IOE)</name>
    <style>none</style>
    <subject>Your patient {!Guardant_360_Sample__c.MR_Patient_Initials__c}&apos;s genomic alteration indicates potential eligibility for a recently FDA approved targeted therapy</subject>
    <textOnly>Dear Dr. {!Contact.LastName},

The Guardant360 test you ordered to identify circulating tumor biomarkers for your patient {!Guardant_360_Sample__c.MR_Patient_Initials__c} reported {!Guardant_360_Sample__c.MR_Qualifying_Target_Alterations__c} on {!Guardant_360_Sample__c.Final_Report_Date__c}. We found that this uncommon alteration could qualify your patient for a recently FDA approved therapy.

If you would like to receive more information, please reply to this email.

To view your Guardant360 report in our secure online portal, click here: {!Guardant_360_Sample__c.Portal_Link_for_MD__c}.

Sincerely,  

Adriana Olar, MD  
Clinical Trial Advisor  
Guardant Health, Inc.  
On behalf of the Clinical Trial Advisors program

This message is intended solely for the designated recipient(s). It may contain confidential or proprietary information and may be subject to attorney-client privilege or other confidentiality protections. If you are not a designated recipient you may not review, copy or distribute this message. If you have received this in error, please notify the sender by replying to this e-mail and deleting this message. Thank you.</textOnly>
    <type>custom</type>
    <uiType>Aloha</uiType>
</EmailTemplate>
